Inhalation of high concentration hydrogen gas improves short-term outcomes in a rat model of asphyxia induced-cardiac arrest.
Lei Huang, Richard L Applegate, Patricia M Applegate, Warren Boling, John H Zhang · Medical gas research · 2018
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In rats, during the 1 hour observation time at 48 hours post-resuscitation, seizures were observed in 50% of ACA and 20% of ACA + H₂ pre- & post-treatment rats ( Table 3 ); however, this difference did not reach statistical significance. The average time between the start of asphyxia and MAP decrease to 30 mmHg (80% decrease from the baseline) was 217 ± 28 seconds in ACA control, 225 ± 18 seconds in ACA + H₂ post-treatment and 223 ± 19 seconds in ACA + H₂ pre- & post-treatment groups, respectively, with no significant difference among the three groups ( P = 0.309). These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how inhaled hydrogen gas affected the outcomes measured in rats. During the 1 hour observation time at 48 hours post-resuscitation, seizures were observed in 50% of ACA and 20% of ACA + H₂ pre- & post-treatment rats ( Table 3 ); however, this difference did not reach statistical significance.
What the Researchers Studied
The researchers studied rats. The study used a preclinical animal experiment.
What Effects Did Molecular Hydrogen Have?
Reported treatment duration: 1 hour. During the 1 hour observation time at 48 hours post-resuscitation, seizures were observed in 50% of ACA and 20% of ACA + H₂ pre- & post-treatment rats ( Table 3 ); however, this difference did not reach statistical significance. The authors concluded that of this preclinical study suggest that water electrolysis-derived 60% hydrogen gas may improve short-term outcomes in cardiogenic global brain hypoxia-ischemia.
Why These Findings Matter
These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The research population or model was rats. The reported sample size was 56. The study used a preclinical animal experiment. The hydrogen delivery method was inhaled hydrogen gas. The reported treatment duration was 1 hour.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.